Written by: Jonathan Alsop, PhD; Lawrence Pont, MSc | Posted on: | Category: MAIC
MAIC

Matching-adjusted indirect comparison via a polynomial-based non-linear optimisation method

Reimbursement authorities need the best available evidence when comparing treatments. This evidence is arguably best obtained from randomised controlled trials. However, for many valid scientific and commercial reasons, ...

Read More
Written by: PD Dr. rer. nat. Hans-Peter Dürr | Posted on: | Category: Epidemiology
SARS-CoV-2

Corona Pandemic: Future Considerations Based on Epidemiological Modelling Results

Since the emergence of the corona pandemic, there has been a worldwide question regarding when the pandemic would come to an end. In the meantime, such hopes are increasingly being supplanted by concerns that this infectious ...

Read More
IQWiG Lifebuoy
Written by: PD Dr. Hans-Peter Dürr | Posted on: | Category: HTA

Can a significant effect remain if we re-analyze it in a subpopulation with lower N?

In the benefit assessment of drugs, it may happen that a benefit must be re-examined in a subpopulation, for example if the approval is restricted to a subpopulation which particularly benefits from the treatment. In these ...

Read More
Written by: Jonathan Alsop, PhD | Posted on: | Category: MAIC

Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer

This recently published MAIC is an interesting one. The authors have clearly gone to great lengths to identify and adjust for potential treatment-effect ...

Read More
Categories

By clicking "Accept," you agree to the use of Numerus and third party cookies and other similar technologies to enhance your browsing experience, analyse, and measure your engagement with our content.